SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak
- Conditions
- Sars-CoV2
- Interventions
- Diagnostic Test: Serological testing
- Registration Number
- NCT04426292
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Brief Summary
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to the rest of the world, including Europe and explicitly affects the respiratory system, generating Coronavirus disease 2019 (COVID-19).
This study is a monocentric interventional prospective cohort study. After signing a written informed consent, participants will be recruited for questionnaire completion and blood sampling. Sample storage and analysis will be performed at the laboratory of microbiology of the UZ Brussel.
* To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5.
* To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 3500
- Any adult employee of the UZ Brussel who provided a signed informed consent to participate in the study.
- UZ Brussel employees whose contract expires within 6 months of study initiation, with the exception of resident trainees (if training continues in another hospital, resident trainees will be asked to perform the last sampling when leaving the UZ Brussel).
- Staff not active during the inclusion period
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description General arm Serological testing All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
- Primary Outcome Measures
Name Time Method Seroprevalence Change from baseline to 2 months and 5 months timepoint - To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5.
seroconversions Change from baseline to 2 months and 5 months timepoint - To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.
- Secondary Outcome Measures
Name Time Method Incidence of probable cases Change from baseline to 2 months and 5 months timepoint - To document the incidence of new probable cases of COVID-19 (based on study questionnaire) among employees of the UZ Brussel over a period of five months.
Incidence of definite cases Change from baseline to 2 months and 5 months timepoint - To document the incidence of new definite cases of COVID-19 (based on self-reported positive PCR testing on nasopharyngeal swab) among employees of the UZ Brussel over a period of five months.
Antibody kinetics Change from baseline to 2 months and 5 months timepoint - To document the SARS-CoV-2 antibody kinetics after confirmed and probable COVID-19. Specifically (1) electrostatic interactions, (2) dispersion forces, (3) hydrogen bonds, and (4) hydrophobic interactions.
Proportion of asymptomatic seroconversions Change from baseline to 2 months and 5 months timepoint - To quantify the proportion of asymptomatic seroconversions among employees of the UZ Brussel over a period of five months.
Potential work-related risk factors Change from baseline to 2 months and 5 months timepoint - To investigate potential work-related risk factors for SARS-CoV-2 infection among employees of the UZ Brussel.
Concerns for safety for infection with COVID-19 Change from baseline to 2 months and 5 months timepoint - To document the concerns of HCW and non-HCW about their safety for infection with COVID-19.
Trial Locations
- Locations (1)
UZ Brussel
🇧🇪Jette, Brussel, Belgium